St. Baldrick’s Foundation Awards $1.4 Million in Fellowships to Advance Childhood Cancer Research
Los Angeles, California--(Newsfile Corp. - March 6, 2025) - The St. Baldrick's Foundation, the largest charity funder of childhood cancer...
Brain
Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP
March 6, 2025 Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study...
Achieve Life Sciences to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call and Webcast on March 11, 2025
SEATTLE and VANCOUVER, British Columbia, March 06, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty...
Hemostemix and FireFly Neuroscience’s Brain Network Analytics (BNA(TM)) Engage to Complete Phase 1 Vascular Dementia Clinical Trial of ACP-01
A growing body of clinical evidence supports the use of Firefly's FDA-Cleared BNA(TM) platform to study ACP-01 as a treatment...
Linus Health Achieves Landmark Research Recognition Across Peer-Reviewed Medical and Scientific Journals
Research validates the efficacy and accuracy of its digital solutions designed to detect early indicators of cognitive impairment BOSTON, March...
NeuroOne® to Present at the Oppenheimer 35th Annual Healthcare MedTech & Services Conference
EDEN PRAIRIE, Minn., March 05, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a...
Business Plan Contest “Photonics Challenge 2025” was Successfully Held in Hamamatsu City, the Center of the Optical Industry
Three companies with outstanding optical technology – Beyond Optical Medical Technologies, Ectobrain Devices and Catana Corporation – presented groundbreaking ideas and...
Cingulate Reports Safety Results from Final Phase 3 Trials for Lead ADHD Asset CTx-1301: On Track to File for FDA Approval Mid-2025
Results Have Been Submitted Ahead of In-Person Meeting with FDA Set for April 2 CTx-1301 is the First, True, Once-Daily...
ABM of PPC Inc. Unveils the World’s First Emotion Processing Unit (EPU) Chip: A 10 Trillion dollar Industry Disruptor Transforming Neuroscience, Mental Health, Military Strategy & Human Performance
Boston, March 3, 2025 /PRNewswire/ -- Advanced Brain Methodologies Inc. (ABM) a division of Primary & Preventive Care Inc., has...
Protega Pharmaceuticals collaborates with Wellgistics Health to support pharmacist education and increase patient access to the first and only FDA-approved abuse-deterrent immediate-release opioid, ROXYBOND™
ROXYBOND, formulated with patented, first-of-its-kind abuse-deterrent technology SentryBond™, is designed to provide multiple levels of protection PRINCETON, N.J., March 3, 2025...
Nexalin Technology Receives Notice of Allowance from the USPTO for Patent Covering Deep Intracranial Frequency Stimulation (DIFS™) Technology for Opioid and Other Substance Use Disorders
Patent Strengthens Nexalin’s Intellectual Property Portfolio and Highlights the Potential of DIFS™ Technology in Addressing Substance Use Disorders, Including Opioids,...
Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors
NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small-molecule...
NKGen Biotech Announces Administration of First Dose of Troculeucel to Stroke Patient Under FDA-Cleared Compassionate Use Program
NKGen explores the use of troculeucel as a potential treatment option for post-stroke patients.SANTA ANA, Calif., March 03, 2025 (GLOBE...
Revive Therapeutics Announces LOI to Acquire DiagnaMed’s Molecular Hydrogen Program
TORONTO, March 03, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a...
Annexon Reports Fourth Quarter and Year-End 2024 Financial Results, Portfolio Progress and Key Anticipated Milestones
Robust, Consistent Phase 3 Data and Real-World Evidence Outcomes Support ANX005 as Potential First Targeted Therapy for GBS; Pre-BLA Meeting...
Cassava Sciences Reports 2024 Financial Results and Provides Business Update
Top-line data for REFOCUS-ALZ, the second Phase 3 study of simufilam in Alzheimer’s disease, expected late first-quarter/early second-quarter 2025License agreement...
Neuphoria Therapeutics to Ring the Nasdaq Opening Bell on March 3rd, 2025
BURLINGTON, Mass., March 03, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (Neuphoria or Company), ”), a clinical-stage biotechnology...
NeuralCure AI Partners with Leading Medical Imaging Provider to Enhance AI-Powered Diagnostic Support for Physicians
AI-Driven Insights to Be Integrated with Life Imaging FLA's Full-Body CT Scan Services Through Their Upcoming 200 Location Expansion DENVER...
Noom Expands into Hormone Replacement Therapy to Support Women’s Health and Well-being
Noom + HRTRx blends Noom’s proven behavior change program with HRT medication to achieve whole-person healthThe new offering builds on...
Nexalin Technology Announces Initiation of Patient Recruitment for UCSD’s TBI & PTSD Clinical Study Following IRB Approval
HALO™ Clarity Devices Successfully Shipped for First Phase of Clinical TrialsHOUSTON, TX, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology,...